Rewriting the Aging Program
Gene therapy was originally developed to treat rare genetic diseases by delivering a functional copy of a broken gene. But a growing number of researchers are asking a bolder question: what if gene therapy could treat aging itself? Not by fixing a single mutation, but by delivering genes that actively rejuvenate cells, clear damage, or restore youthful function.
The logic is straightforward. Aging involves the decline of specific biological programs — DNA repair, protein recycling, anti-inflammatory signaling, muscle maintenance, hormone production. If we can identify genes that bolster these programs, and deliver them to the right tissues, we might be able to counteract aging at its source.
Animal experiments are delivering results that would have seemed like science fiction a decade ago. And the first humans have already tried it.
AAV-Delivered OSK: Epigenetic Rejuvenation by Gene Therapy
One of the most striking gene therapy approaches to aging uses adeno-associated virus (AAV) vectors to deliver the Yamanaka factors OCT4, SOX2, and KLF4 — the OSK system — directly into living tissues. Unlike the full four-factor OSKM system, OSK omits c-MYC, a potent oncogene, which dramatically improves the safety profile.
David Sinclair's lab at Harvard demonstrated the power of this approach in a landmark 2020 study. They used AAV to deliver OSK factors to the retinal ganglion cells of aged mice. The treatment reversed age-related vision loss, regenerated damaged optic nerve axons, and restored youthful DNA methylation patterns. Remarkably, the rejuvenation depended on DNA demethylation mediated by TET enzymes, suggesting that the cells were accessing an endogenous program for epigenetic repair.
Subsequent work extended these findings to other tissues. Systemic delivery of AAV-OSK in aged mice showed improvements in kidney and muscle function, with epigenetic clock measurements confirming a reduction in biological age. The key innovation was making the transgene expression inducible — activated by a drug (doxycycline) that could be administered and withdrawn, giving researchers precise control over the dose and duration of reprogramming.
The challenge of scaling this approach to humans is considerable. AAV vectors have limited packaging capacity, and delivering three transcription factors efficiently requires careful vector design. Immune responses to AAV can limit repeat dosing. And the optimal reprogramming regimen — how much, how long, how often — still needs extensive safety testing. But the proof of concept is powerful.
Follistatin Gene Therapy: Fighting Muscle Loss
Sarcopenia — the progressive loss of muscle mass and strength with age — is one of the most debilitating aspects of aging. It increases fall risk, reduces independence, and accelerates overall decline. Follistatin, a naturally occurring protein that inhibits myostatin (a negative regulator of muscle growth), has emerged as a promising gene therapy target.
In preclinical studies, AAV-delivered follistatin increased muscle mass and strength in mice and non-human primates. The treatment worked by blocking myostatin's brake on muscle growth, allowing aged muscles to hypertrophy and regain youthful function. Importantly, the effects were durable — a single injection of AAV-follistatin produced sustained increases in muscle mass without requiring repeated dosing.
Brian Hanley, a microbiologist and self-experimenter, injected himself with a follistatin gene therapy construct in 2015, becoming one of the first humans to undergo gene therapy for a non-disease indication. While his self-report suggested increased muscle mass, the uncontrolled nature of the experiment limited its scientific value.
More rigorous clinical efforts are underway. Several biotech companies are developing follistatin or myostatin-targeting gene therapies for muscle-wasting conditions like inclusion body myositis and spinal muscular atrophy. While these programs target specific diseases, the same approach could theoretically be applied to age-related sarcopenia once the regulatory pathway is established.
Klotho Overexpression: The Anti-Aging Hormone
Klotho is a protein whose discovery reads like a parable about aging. Named after the Greek goddess who spins the thread of life, klotho was identified in 1997 when researchers found that mice lacking the gene aged rapidly and died prematurely, while mice overexpressing it lived 20 to 30 percent longer than normal.
Klotho functions as a circulating hormone that declines with age. It suppresses insulin/IGF-1 signaling, reduces oxidative stress, inhibits the Wnt pathway in certain contexts, and supports kidney function. Low klotho levels are associated with cardiovascular disease, kidney disease, cognitive decline, and reduced lifespan in humans.
Gene therapy to increase klotho expression has shown remarkable results in animal models. AAV-delivered klotho improved cognitive function in aged mice, reduced kidney fibrosis, and attenuated atherosclerosis. Intriguingly, a single injection of klotho protein into the brains of aged mice improved synaptic plasticity and memory — suggesting that even transient elevation of klotho levels can have lasting benefits.
Unity Biotechnology and several academic labs are exploring klotho-based therapies. The challenge is determining the optimal delivery route and dose — klotho has complex, tissue-specific effects, and too much could have unintended consequences on phosphate metabolism and mineral homeostasis.
Liz Parrish and BioViva: The First Human Gene Therapy for Aging
In 2015, Elizabeth Parrish, CEO of BioViva Sciences, made headlines by announcing that she had undergone two experimental gene therapies intended to combat aging: one delivering telomerase (hTERT) to lengthen her telomeres, and another delivering follistatin to counteract muscle loss. The treatments were administered in Colombia, outside the jurisdiction of the FDA.
Parrish reported that her leukocyte telomere length increased from 6.71 kb to 7.33 kb following the telomerase treatment — an apparent reversal of roughly 20 years of telomere shortening. The follistatin treatment, she claimed, resulted in increased lean muscle mass.
The scientific community's reaction was mixed to skeptical. The experiment was uncontrolled, had a sample size of one, relied on telomere measurements with significant technical variability, and was not published in a peer-reviewed journal. Critics argued that it was premature, potentially dangerous, and set a troubling precedent for self-experimentation with gene therapy.
Supporters countered that Parrish accelerated a conversation that the regulatory system was too slow to have, and that her willingness to serve as her own test subject demonstrated genuine conviction. Regardless of one's view, the BioViva experiment marked a cultural milestone: the first time a human deliberately used gene therapy to try to reverse aging.
BioViva has continued developing its platform and has explored additional gene therapy targets for aging, including klotho and SIRT6. The company advocates for patient-directed access to gene therapies and has been a vocal participant in debates about the regulatory framework for longevity interventions.
The Current Clinical Landscape
As of 2026, the clinical pipeline for anti-aging gene therapy is expanding but still largely preclinical. The most advanced programs are disease-specific therapies that target age-related conditions rather than aging itself.
Ophthalmology has emerged as a leading target for gene therapy in aging because the eye is small, accessible, and immunologically privileged. AAV-delivered gene therapies for age-related macular degeneration (AMD) and glaucoma are in clinical trials. If OSK-based rejuvenation of retinal cells translates from mice, the eye could be the first organ where epigenetic reprogramming is tested in humans.
Musculoskeletal gene therapies targeting follistatin, myostatin inhibitors, and growth factors are in development for sarcopenia and osteoarthritis.
Cardiovascular gene therapies delivering protective factors like klotho, VEGF, and anti-inflammatory cytokines are being explored for atherosclerosis and heart failure.
Neurological gene therapies targeting neurotrophic factors and anti-inflammatory genes are in trials for Alzheimer's and Parkinson's — diseases whose primary risk factor is age.
Challenges and Promise
Anti-aging gene therapy faces several major hurdles. AAV manufacturing is expensive and difficult to scale. Immune responses can limit efficacy and prevent repeat dosing. Long-term safety data for constitutive expression of rejuvenation genes does not yet exist in humans. And the regulatory framework for treating "aging" — which is not classified as a disease by most regulatory agencies — remains unclear.
Yet the trajectory is unmistakable. Each year brings more sophisticated vector designs, better tissue targeting, improved safety switches, and stronger preclinical data. The first approved gene therapies for age-related diseases will likely arrive before therapies targeting aging directly. But as the scientific and regulatory groundwork is laid disease by disease, tissue by tissue, the path to comprehensive anti-aging gene therapy becomes clearer.
We are watching the earliest chapters of what may become medicine's most ambitious project: rewriting the human body's relationship with time.
Sources & Further Reading
- Lu, Y. et al. "Reprogramming to recover youthful epigenetic information and restore vision." Nature 588, 124–129 (2020).
- Macip, C.C. et al. "Gene therapy–mediated partial reprogramming extends lifespan." Nature Aging 4, 1177–1193 (2024).
- Life Biosciences ER-100 FDA IND Clearance — First FDA-cleared partial reprogramming therapy for optic neuropathies, 2026.
- Sinclair Lab Research — Harvard Medical School.
Last updated: March 2026.
